Clinical trial NCT04231513: A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants
Official title: A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2814 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: E2814
Healthy Participants
Phase 1
Pharmacokinetics
Pharmacodynamics
Immunogenicity
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
First posted: 2020-01-18
Enrollment: 72
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: OTHER

Brief summary: The primary objective of this study is to evaluate the safety and tolerability of single and multiple intravenous infusions of E2814 in healthy adult participants.

Detailed description: The study is comprised of two components: a single ascending dose (SAD) component and a multiple ascending dose (MAD) component. The SAD component consists of 5 sequential cohorts and in each cohort, 8 healthy participants are randomized (3:1) to receive a single dose of E2814 or E2814-matched placebo. The MAD component of the study consists of 4 sequential cohorts and in each cohort, 8 healthy participants are randomized (3:1) to receive E2814 or E2814-matched placebo every 4 weeks (Q4W) on 3 occasions.

Eligibility criteria: Inclusion Criteria:

1. Nonsmoking, healthy participants.

Japanese participants must satisfy the following requirements:

1. Must have been born in Japan to Japanese parents and Japanese grandparents
2. Must have lived no more than 5 years outside of Japan
3. Must not have changed their life style or habits, including diet, while living outside of Japan

Exclusion Criteria:

1. Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
2. Females who are breastfeeding or pregnant at Screening or Baseline
3. Females of childbearing potential who within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:

   1. total abstinence (if it is their preferred and usual lifestyle)
   2. an intrauterine device or intrauterine hormone-releasing system
   3. a contraceptive implant
   4. an oral contraceptive (Participants must be on a stable dose of the same oral contraceptive product for at least 28 days before dosing and throughout the study and for 16 weeks after study drug discontinuation)
   5. have a vasectomized partner with confirmed azoospermia Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 16 weeks after study drug discontinuation NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
4. Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (that is, not of childbearing potential or practicing highly effective contraception throughout the study period and for 5 times the half-life of the study drug plus 90 days after study drug discontinuation). If the female partner is pregnant, then males who do not agree to use latex, or synthetic condoms throughout the study period and for 90 days after study drug discontinuation. No sperm donation is allowed during the study period and for 5 times the half-life of the study drug plus 90 days after study drug discontinuation
5. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
6. Any clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, ECG finding, or laboratory test results that requires medical treatment at Screening or Baseline
7. A prolonged QT (that is, corrected QT interval \[QTc\] Fridericia interval greater than \[\>\] 450 milliseconds) demonstrated on ECG at Screening or Baseline. A history of risk factors for torsade de pointes (example, heart failure, hypokalemia, family history of long QT Syndrome)
8. Persistent systolic blood pressure (SBP) \>130 millimeters of mercury (mmHg) or diastolic blood pressure (DBP) \>85 mmHg at Screening or Baseline. One repeat measurement will be allowed
9. Heart rate less than 45 or more than 100 beats per minute at Screening or Baseline
10. Known history of clinically significant drug allergy at Screening or Baseline
11. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening or Baseline
12. Any history of hypersensitivity reaction to a foreign protein, with clinical features of Grades 2 to 4 as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, immunoglobulin A (IgA) deficiency, or significant autoimmune disease or disorder. Participants with hypersensitivity reactions to foreign protein with clinical features limited to nasal or conjunctival symptoms such as in allergic rhinitis do not need to be excluded
13. Known to be human immunodeficiency virus (HIV) positive at Screening
14. Active or chronic (including asymptomatic) viral hepatitis (A, B or C) as demonstrated by positive serology at Screening. For hepatitis B serology, this refers to positive for hepatitis B core antibody (HBcAb, Immunoglobulin M \[IgM\] type) or hepatitis B surface or core antigens (HBsAg, HBcAg). For hepatitis C serology, a positive result for screening serological testing must be confirmed by qualitative hepatitis C virus ribonucleic acid (RNA)
15. History of drug or alcohol dependency or abuse within the 2 years before Screening, or those who have a positive urine drug test or breath (or urine) alcohol test at Screening or Baseline
16. Intake of over-the-counter medications within 2 weeks before dosing
17. Currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 half-lives, whichever is longer) preceding informed consent
18. Exposure to any biologic drug within 90 days or at least 5 half-lives (whichever is longer), or within 4 weeks for vaccines, before Screening, with the exception of influenza and COVID-19 vaccinations that are allowed up to 7 days before dosing
19. Engagement in strenuous exercise within 2 weeks before check-in (example, marathon runners, weight lifters, etc.)
20. Any contraindication to continuous cerebrospinal fluid (CSF) sampling via indwelling lumbar catheter or via lumbar puncture (LP)
21. Any history of or current blood clotting or bleeding disorder that is not under adequate control, including a platelet count less than (\<) 50,000, international normalized ratio (INR) \>1.3, or partial thromboplastin time (PTT) \>upper limit of normal (ULN), or fibrinogen \<1.8 gram per liter (g/L) or \>4.3 g/L at Screening or Baseline. Participants receiving anticoagulation therapy or identified at risk for hemorrhage
22. Any lifetime suicidal behavior or psychiatric disease. Whenever possible, medical records should be reviewed to confirm absence of history of psychiatric disease or use of medications to treat psychiatric disease
23. Any current or prior history of suicidal behavior or psychiatric disease identified by the psychiatrist at the Screening Visit

Primary outcomes:
measure: SAD, Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
timeFrame: Up to 113 days
measure: SAD, Number of Participants With Clinically Significant Laboratory Values
timeFrame: Up to 113 days
measure: SAD, Number of Participants With Clinically Significant Vital Signs Values
timeFrame: Up to 113 days
measure: SAD, Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
timeFrame: Up to 113 days
measure: MAD, Number of Participants With TEAEs and SAEs
timeFrame: Up to 169 days
measure: MAD, Number of Participants With Clinically Significant Laboratory Values
timeFrame: Up to 169 days
measure: MAD, Number of Participants With Clinically Significant Vital Signs Values
timeFrame: Up to 169 days
measure: MAD, Number of Participants With Clinically Significant ECG Findings
timeFrame: Up to 169 days
Secondary outcomes:
measure: SAD, Cmax Serum: Maximum Observed Concentration for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, Tmax Serum: Time to Reach the Maximum Observed Concentration (Cmax) for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, AUC (0-24h) Serum: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814
timeFrame: Pre-dose (Day 1) and up to 24 hours Post Dose
measure: SAD, AUC (0-72h) Serum: Area Under the Concentration-time Curve From Time Zero to 72 Hour for E2814
timeFrame: Pre-dose (Day 1) and up to 72 hours Post Dose
measure: SAD, AUC (0-inf) Serum: Area Under the Concentration-time Curve from Time 0 to Infinity for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, t½ Serum: Terminal Elimination Phase Half-life for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, CL Serum: Clearance for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, Vz Serum: Volume of Distribution for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, Serum anti-E2814 Antibody Concentration
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, Cmax CSF: Maximum Observed Concentration for E2814
timeFrame: Pre-dose (Day 1) and up to Day 29 Post Dose
measure: SAD, Tmax CSF: Time to Reach the Maximum Observed Concentration (Cmax) for E2814
timeFrame: Pre-dose (Day 1) and up to Day 29 Post Dose
measure: SAD, AUC (0-24h) CSF: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814
timeFrame: Pre-dose (Day 1) and up to 24 hours Post Dose
measure: SAD, Cmax Plasma: Maximum Observed Concentration for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, Tmax Plasma: Time to Reach the Maximum Observed Concentration (Cmax) for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, AUC (0-24h) Plasma: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814
timeFrame: Pre-dose (Day 1) and up to 24 hours Post Dose
measure: SAD, AUC (0-72h) Plasma: Area Under the Concentration-time Curve From Time Zero to 72 Hour for E2814
timeFrame: Pre-dose (Day 1) and up to 72 hours Post Dose
measure: SAD, AUC (0-inf) Plasma: Area Under the Concentration-time Curve from Time 0 to Infinity for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, t½ Plasma: Terminal Elimination Phase Half-life for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, CL Plasma: Clearance for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, Vz Plasma: Volume of Distribution for E2814
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: SAD, Plasma anti-E2814 Antibody Concentration
timeFrame: Pre-dose (Day 1) and up to Day 113 Post Dose
measure: MAD, Cmax Serum: Maximum Observed Concentration for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Tmax Serum: Time to Reach the Maximum Observed Concentration (Cmax) for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, AUC (0-24h) Serum: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814
timeFrame: Pre-dose (Day 1) and up to 24 hours Post Dose
measure: MAD, AUC (0-72h) Serum: Area Under the Concentration-time Curve From Time Zero to 72 Hour for E2814
timeFrame: Pre-dose (Day 1) and up to 72 hours Post Dose
measure: MAD, AUC (0-tau) Serum: Area Under the Concentration-time Curve From Zero Time to the end of the Dosing Interval for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, t½ Serum: Terminal Elimination Half-life for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, CL Serum: Clearance for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Vz Serum: Volume of Distribution for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Rac(Cmax) Serum: Ratio of Accumulation for Cmax for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Rac(AUC) Serum: Ratio of Accumulation for AUC for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Serum anti-E2814 Antibody Concentration
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, CSF Concentration for E2814
timeFrame: Pre-dose (Day 1) and up to Day 85 Post Dose
measure: MAD, Cmax Plasma: Maximum Observed Concentration for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Tmax Plasma: Time to Reach the Maximum Observed Concentration (Cmax) for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, AUC (0-24h) Plasma: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814
timeFrame: Pre-dose (Day 1) and up to 24 hours Post Dose
measure: MAD, AUC (0-72h) Plasma: Area Under the Concentration-time Curve From Time Zero to 72 Hour for E2814
timeFrame: Pre-dose (Day 1) and up to 72 hours Post Dose
measure: MAD, AUC (0-tau) Plasma: Area Under the Concentration-time Curve From Zero Time to the end of the Dosing Interval for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, t½ Plasma: Terminal Elimination Half-life for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, CL Plasma: Clearance for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Vz Plasma: Volume of Distribution for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Rac(Cmax) Plasma: Ratio of Accumulation for Cmax for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Rac(AUC) Plasma: Ratio of Accumulation for AUC for E2814
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
measure: MAD, Plasma anti-E2814 Antibody Concentration
timeFrame: Pre-dose (Day 1) and up to Day 169 Post Dose
Other outcomes:
Locations:
city: Glendale
country: United States
facility: California Clinical Trials Medical Group/Parexel International
state: California
city: San Antonio
country: United States
facility: Worldwide Clinical Trials
state: Texas
Study officials:
References: